New combo therapy shows promise against hard-to-treat leukemia

This study tests whether adding a targeted drug called tafasitamab to standard chemotherapy can improve outcomes for adults newly diagnosed with a fast-growing blood cancer (B-ALL) that lacks the Philadelphia chromosome. About 32 adults who are not good candidates for more intensive pediatric-style treatment will receive the combination. The main goal is to see if more patients achieve a deep remission (no detectable cancer cells) after one cycle of treatment.